Concepedia

Author

Paul Bessette

Université de SherbrookeORCID

Also Known As

Bessette, P, Bessette, Paul, Denise Avard, P Bessette, P. Bessette, Paul Bessette, Suzanne Fortin

78

Publications

4K

Citations

28

H-Index

49

Concepts

All Affiliations

Université de SherbrookeCentre Hospitalier Universitaire de SherbrookeUniversity College LondonPrincess Margaret Cancer CentreUniversity of Manchester
PB

About

Paul Bessette is an author at Université de Sherbrooke specializing in medicine, gynecology oncology, and ovarian cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

17

892

2

Health Sciences

2

2

39

3

Public Health

2

2

95

4

Cell Biology

2

2

90

5

Kinesiology

1

1

11

Paul Bessette

×

38

Publications

3.8K

Citations

27

H-Index

YearCitations

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia León‐Castillo, Stephanie M. de Boer, Melanie Powell,

Journal of Clinical Oncology

2020

777

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin,

The Lancet Oncology

2018

599

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin,

The Lancet Oncology

2019

432

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Bradley J. Monk, Christine Parkinson, Myong Cheol Lim,

Journal of Clinical Oncology

2022

346

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Ignace Vergote, Corneel Coens, Matthew Nankivell,

The Lancet Oncology

2018

290

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin,

The Lancet Oncology

2016

176

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

Cathalijne Post, Ellen Stelloo, Vincent T.H.B.M. Smit,

JNCI Journal of the National Cancer Institute

2021

94

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling

Denis Lane, Isabelle Matte, Claude Laplante,

Molecular Cancer

2016

86

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial

Sven� Mahner, Werner Meier, Andreas du Bois,

European Journal of Cancer

2014

68

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Diane Provencher, C. Gallagher, Wendy R. Parulekar,

Annals of Oncology

2017

66

Page 1